1. J Clin Oncol. 2019 Nov 1;37(31):2857-2865. doi: 10.1200/JCO.19.00456. Epub
2019  Sep 12.

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in 
Children: An International Observational Study.

Donadieu J(1), Larabi IA(2), Tardieu M(3), Visser J(4), Hutter C(5), Sieni E(6), 
Kabbara N(7)(8), Barkaoui M(1), Miron J(1), Chalard F(1), Milne P(9), Haroche 
J(10), Cohen F(10), Hélias-Rodzewicz Z(11), Simon N(12), Jehanne M(13), Kolenova 
A(14), Pagnier A(3), Aladjidi N(15), Schneider P(16), Plat G(17), Lutun A(18), 
Sonntagbauer A(19), Lehrnbecher T(19), Ferster A(20), Efremova V(21), Ahlmann 
M(22), Blanc L(23), Nicholson J(4), Lambilliote A(24), Boudiaf H(25), Lissat 
A(26), Svojgr K(27), Bernard F(28), Elitzur S(29), Golan M(30), Evseev D(31), 
Maschan M(31), Idbaih A(32), Slater O(33), Minkov M(5), Taly V(34), Collin M(9), 
Alvarez JC(2), Emile JF(11), Héritier S(1)(11).

Author information:
(1)Trousseau Hospital, Paris, France.
(2)Centre Hospitalier Universitaire R.-Poincaré, Garches, France.
(3)Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
(4)Cambridge University Hospitals, Cambridge, United Kingdom.
(5)Medical University of Vienna, Vienna, Austria.
(6)Azienda Ospedaliero-Universitaria A. Meyer, Florence, Italy.
(7)Centre Hospitalier du Nord, Zgharta, Lebanon.
(8)Rafic Hariri University Hospital, Beirut, Lebanon.
(9)Newcastle University, Newcastle upon Tyne, United Kingdom.
(10)Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.
(11)Université Paris-Saclay, Boulogne-Billancourt, France.
(12)Hôpital Sainte Marguerite, Marseille, France.
(13)Centre Hospitalier Universitaire Félix-Guyon (Saint-Denis), La Réunion, 
France.
(14)Comenius University Children's Hospital Limbova 1, Bratislava, Slovakia.
(15)Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
(16)Centre Hospitalier Universitaire de Rouen, Rouen, France.
(17)Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
(18)Centre Hospitalier Universitaire d'Amiens, Amiens, France.
(19)Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
(20)Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
(21)University Hospital, Minsk, Belarus.
(22)Universitätsklinikum Münster Klinik für Kinder- und 
Jugendmedizin-Pädiatrische Hämatologie und Onkologie, Münster, Germany.
(23)Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
(24)Centre Hospitalier Universitaire de Lille, Lille, France.
(25)Hôpital Mustapha, Mustapha, Algeria.
(26)Charité-University Medicine Berlin, Berlin, Germany.
(27)University Hospital Motol, Prague, Czech Republic.
(28)Hôpitaux Universitaires de Genève, Geneva, Switzerland.
(29)Schneider Children's Medical Center, Petah Tikva, Israel.
(30)The Edmond and Lily Safra Children's Hospital, Tel-Hahsomer, Israel.
(31)Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and 
Immunology, Moscow, Russia.
(32)Centre Hospitalier Universitaire La Pitié-Salpêtrière-Charles Foix, Paris, 
France.
(33)Great Ormond Street Hospital, London, United Kingdom.
(34)Université Paris Sorbonne Cité, Paris, France.

PURPOSE: Off-label use of vemurafenib (VMF) to treat BRAFV600E 
mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was 
evaluated.
PATIENTS AND METHODS: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. 
They were classified according to risk organ involvement: liver, spleen, and/or 
blood cytopenia. The main evaluation criteria were adverse events (Common 
Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses 
according to Disease Activity Score.
RESULTS: LCH extent was distributed as follows: 44 with positive and 10 with 
negative risk organ involvement. Median age at diagnosis was 0.9 years (range, 
0.1 to 6.5 years). Median age at VMF initiation was 1.8 years (range, 0.18 to 14 
years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas 
median treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 
38 complete responses and 16 partial responses had been achieved, with the 
median Disease Activity Score decreasing from 7 at diagnosis to 0 (P < .001). 
Skin rash, the most frequent adverse event, affected 74% of patients. No 
secondary skin cancer was observed. Therapeutic plasma VMF concentrations 
(range, 10 to 20 mg/L) seemed to be safe and effective. VMF discontinuation for 
30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, 
assessed as circulating cell-free DNA, decreased after starting VMF but remained 
positive (median, 3.6% at diagnosis, and 1.6% during VMF treatment; P < .001) 
and was associated with a higher risk of reactivation at VMF discontinuation. 
None of the various empirical therapies (hematopoietic stem-cell 
transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) 
used for maintenance could eradicate the BRAFV600E clone.
CONCLUSION: VMF seemed safe and effective in children with refractory 
BRAFV600E-positive LCH. Additional studies are needed to find effective 
maintenance therapy approaches.

DOI: 10.1200/JCO.19.00456
PMCID: PMC6823889
PMID: 31513482 [Indexed for MEDLINE]